157 related articles for article (PubMed ID: 21833762)
1. In vitro-in situ permeability and dissolution of fexofenadine with kinetic modeling in the presence of sodium dodecyl sulfate.
Gundogdu E; Mangas-Sanjuan V; Gonzalez-Alvarez I; Bermejo M; Karasulu E
Eur J Drug Metab Pharmacokinet; 2012 Mar; 37(1):65-75. PubMed ID: 21833762
[TBL] [Abstract][Full Text] [Related]
2. Assessment of fexofenadine hydrochloride permeability and dissolution with an anionic surfactant using Caco-2 cells.
Gundogdu E; Gonzalez Alvarez I; Bermejo Sanz M; Karasulu E
Pharmazie; 2011 Oct; 66(10):747-53. PubMed ID: 22026155
[TBL] [Abstract][Full Text] [Related]
3. Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.
Bedada SK; Yellu NR; Neerati P
Pharmacol Rep; 2016 Apr; 68(2):338-43. PubMed ID: 26922536
[TBL] [Abstract][Full Text] [Related]
4. Improved oral bioavailability of fexofenadine hydrochloride using lipid surfactants: ex vivo, in situ and in vivo studies.
Eedara BB; Veerareddy PR; Jukanti R; Bandari S
Drug Dev Ind Pharm; 2014 Aug; 40(8):1030-43. PubMed ID: 23738504
[TBL] [Abstract][Full Text] [Related]
5. The influence of piperine on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy volunteers.
Bedada SK; Boga PK
Eur J Clin Pharmacol; 2017 Mar; 73(3):343-349. PubMed ID: 27981349
[TBL] [Abstract][Full Text] [Related]
6. Multidrug resistance-associated protein 2 is primarily responsible for the biliary excretion of fexofenadine in mice.
Tian X; Zamek-Gliszczynski MJ; Li J; Bridges AS; Nezasa K; Patel NJ; Raub TJ; Brouwer KL
Drug Metab Dispos; 2008 Jan; 36(1):61-4. PubMed ID: 17913796
[TBL] [Abstract][Full Text] [Related]
7. Relative contribution of absorptive and secretory transporters to the intestinal absorption of fexofenadine in rats.
Ujie K; Oda M; Kobayashi M; Saitoh H
Int J Pharm; 2008 Sep; 361(1-2):7-11. PubMed ID: 18572335
[TBL] [Abstract][Full Text] [Related]
8. Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation.
Sultan AA; El Nashar NF; Ashmawy SM; El Maghraby GM
Int J Nanomedicine; 2022; 17():3543-3560. PubMed ID: 35983479
[TBL] [Abstract][Full Text] [Related]
9. Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.
Gundogdu E; Alvarez IG; Karasulu E
Int J Nanomedicine; 2011; 6():1631-40. PubMed ID: 21904453
[TBL] [Abstract][Full Text] [Related]
10. The impact of P-glycoprotein mediated efflux on absorption of 11 sedating and less-sedating antihistamines using Caco-2 monolayers.
Crowe A; Wright C
Xenobiotica; 2012 Jun; 42(6):538-49. PubMed ID: 22188412
[TBL] [Abstract][Full Text] [Related]
11. Transporter-mediated intestinal absorption of fexofenadine in rats.
Kikuchi A; Nozawa T; Wakasawa T; Maeda T; Tamai I
Drug Metab Pharmacokinet; 2006 Aug; 21(4):308-14. PubMed ID: 16946558
[TBL] [Abstract][Full Text] [Related]
12. Regional absorption of fexofenadine in rat intestine.
MacLean C; Moenning U; Reichel A; Fricker G
Eur J Pharm Sci; 2010 Dec; 41(5):670-4. PubMed ID: 20869437
[TBL] [Abstract][Full Text] [Related]
13. Transport characteristics of fexofenadine in the Caco-2 cell model.
Petri N; Tannergren C; Rungstad D; Lennernäs H
Pharm Res; 2004 Aug; 21(8):1398-404. PubMed ID: 15359574
[TBL] [Abstract][Full Text] [Related]
14. Capsaicin pretreatment enhanced the bioavailability of fexofenadine in rats by P-glycoprotein modulation: in vitro, in situ and in vivo evaluation.
Bedada SK; Appani R; Boga PK
Drug Dev Ind Pharm; 2017 Jun; 43(6):932-938. PubMed ID: 28102715
[TBL] [Abstract][Full Text] [Related]
15. Vectorial transport of fexofenadine across Caco-2 cells: involvement of apical uptake and basolateral efflux transporters.
Ming X; Knight BM; Thakker DR
Mol Pharm; 2011 Oct; 8(5):1677-86. PubMed ID: 21780830
[TBL] [Abstract][Full Text] [Related]
16. Enhancing effect of surfactants on fexofenadine.HCl transport across the human nasal epithelial cell monolayer.
Lin H; Gebhardt M; Bian S; Kwon KA; Shim CK; Chung SJ; Kim DD
Int J Pharm; 2007 Feb; 330(1-2):23-31. PubMed ID: 16997520
[TBL] [Abstract][Full Text] [Related]
17. Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Ohura K; Soejima T; Nogata R; Adachi Y; Ninomiya S; Imai T
J Pharm Sci; 2012 Sep; 101(9):3264-74. PubMed ID: 22628163
[TBL] [Abstract][Full Text] [Related]
18. Short-term effect of quercetin on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein, in healthy volunteers.
Kim KA; Park PW; Park JY
Eur J Clin Pharmacol; 2009 Jun; 65(6):609-14. PubMed ID: 19221726
[TBL] [Abstract][Full Text] [Related]
19. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine.
Matsushima S; Maeda K; Hayashi H; Debori Y; Schinkel AH; Schuetz JD; Kusuhara H; Sugiyama Y
Mol Pharmacol; 2008 May; 73(5):1474-83. PubMed ID: 18245269
[TBL] [Abstract][Full Text] [Related]
20. Enantioselective uptake of fexofenadine by Caco-2 cells as model intestinal epithelial cells.
Togami K; Tosaki Y; Chono S; Morimoto K; Hayasaka M; Tada H
J Pharm Pharmacol; 2013 Jan; 65(1):22-9. PubMed ID: 23215684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
